Eli Lilly and Company (NYSE: LLY) announced today that the Australian Therapeutic Goods Administration (TGA) has granted ...

Eli Lilly (NYSE:LLY) witnessed a modest 1.31% increase in its share price over the past week, coinciding with the Australian ...

The decision to register the therapy was supported by data from the Phase III TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 trials.

Australia just approved the first new Alzheimer’s treatment in decades. But before patients get their hopes up, there’s a ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved ...

The Therapeutic Goods Administration has approved a new drug tipped to revolutionise the treatment of hundreds of thousands of Australians suffering through early-stage Alzheimer’s disease.

The Food and Drug Administration approved the drug, now marketed as Kisunla, in July of 2024. It's one of two drugs approved since 2023 that can clear the brain of sticky amyloid plaques ...

This was one woman's experience taking the drug Kisunla. Drugs can't stop Alzheimer's disease yet, but sometimes they can slow it down. MYRA SOLANO GARCIA: Things have just plateaued. I mean ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

Kisunla is the first amyloid-targeting therapy for people with Alzheimer's registered in Australia and the only amyloid plaque-targeting therapy with evidence to support stopping therapy when ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...